Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry

Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry

Abstract Background Real-world studies assessing the comparative effectiveness of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) as first-line targeted therapy are scarce. We analyzed the real-world persistence and effectiveness of etanercept (ETN), adalimumab (ADA...

Full description

Bibliographic Details
Main Authors: Dimitrios A. Pappas, Jacqueline O’Brien, Lin Guo, Ying Shan, Joshua F. Baker, Gregory Kricorian, Scott Stryker, David H. Collier
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Arthritis Research & Therapy
Subjects:
Adalimumab
Biologic/targeted synthetic DMARDs
Etanercept
Janus kinase inhibitors
Patient-reported outcomes
Online Access:https://doi.org/10.1186/s13075-023-03120-9

Internet

https://doi.org/10.1186/s13075-023-03120-9

Similar Items